



PARENTERAL DRUGS (INDIA) LIMITED

Registered Office : E/210, 2nd Floor, Crystal Plaza, Off New Link Road, Andheri West, Mumbai -400053 (Maharashtra)

Website: www.pdindia.com

Date: 14th June, 2022

To,

National Stock Exchange of India Limited
Exchange Plaza
Plot No. C/1, G Block
Bandra Kurla Complex
Bandra (E), Mumbai- 400051.

To,

Bombay Stock Exchange Limited
Phiroze Jeejeebhoy Towers
Rotunda Bldg, Dalal Street
Mumbai- 400051.

Symbol: PDPL

Scrip Code: 524689

Sub: Submission of Disclosures of Related Party Transactions on Consolidated basis pursuant to Regulation 23(9) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Respected Sir/ Ma'am,

Pursuant to Regulation 23(9) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed herewith disclosure of Related Party Transactions on consolidated basis for the half year ended 31st March, 2022.

This is for the information of Exchange and members thereof.

Kindly take the same on record.

Thanking You

Yours Sincerely
for Parenteral Drugs (India) Limited


Govind Das Garg
Whole-Time Director
DIN:00520067

Enclosed: As below

Format for disclosure of related party transactions every six months

Additional disclosure of related party transactions - applicable only in case the related party transaction relates to loans, inter-corporate deposits, advances or investments made or given by the listed entity/subsidiary. These details need to be disclosed only once, during the reporting period when such transaction was undertaken.																		
S. No	Details of the party (listed entity /subsidiary) entering into the transaction		Details of the counterparty			Type of related party transaction (see Note 5)	Value of the related party transaction as approved by the audit committee (see Note 6a)	Value of transaction during the reporting period (see Note 6b)	In case monies are due to either party as a result of the transaction (see Note 1)		In case any financial indebtedness is incurred to make or give loans, inter-corporate deposits, advances or investments			Details of the loans, inter-corporate deposits, advances or investments				
	Name	PAN	Name	PAN	Relationship of the counterparty with the listed entity or its subsidiary				Opening balance	Closing balance	Nature of indebtedness (loan/ issuance of debt/ any other etc.)	Cost (see Note 7)	Tenure	Nature (loan/ advance/ inter-corporate deposit/ investment)	Interest Rate (%)	Tenure	Secured/ unsecured	Purpose for which the funds will be utilised by the ultimate recipient of funds (end-usage)
1	Parenteral Drugs (India) Limited	AAAC P2820L	Infutec Healthcare Limited	AAC CG51 09R	Entities with joint control or significant influence over entity	Sale of Goods	36,00,00,000/-	3,61,71,264/-	59784354/-	95955618/-	-	-	-	-	-	-	-	
						Purchase of Goods		27239753/-	25143560/-	52383313/-	-	-	-	-	-	-		
						Reimbursement of Expenses for Job Work		47444343/-	74420883 /-	121865226/-	-	-	-	-	-	-		
						Advance from Customer		55314410/-	780376813/-	835691223/-	-	-	-	-	-	-		
2	Parenteral Drugs (India) Limited	AAAC P2820L	Mahaganpati Investment Private Limited	AAEC M561 6R	The entity, or any member of a group of which it is a part, provides key management personnel service to the reporting entity or parent of the reporting entity	Loan Given		2000/-	5730261/-	5728261/-	-	-	-	Loan Given	-		Unsecured	
						Loan Taken		1600/-	295929849 /-	295931449/-	-	-	-	Loan Taken	-		Unsecured	
3	Parenteral Drugs (India) Limited	AAAC P2820L	Anitas Exports Private Limited	AAFC A5386 H	The entity, or any member of a group of which it is a part, provides key management personnel service to the reporting entity or parent of the reporting entity	Trade Payable	10,00,000/-	Nil	635660/-	635660/-	-	-	-	-	-	-	-	
						Loans and	10,00,000/-	Nil	567000000	567000000	--	-	-	Loans and	-		Unsecured	

						Advances			/-	/-				Advances				
4	Parenteral Drugs (India) Limited	AAAC P2820L	Parenteral Surgicals	AALC S2658 C	The entity, or any member of a group of which it is a part, provides key management personnel service to the reporting entity or parent of the reporting entity	Loans and Advances	-	Nil	82288265/-	82288265/-	-	-	-	Loans and Advances	-		Unsecured Loan	
5	Parenteral Drugs (India) Limited	AAAC P2820L	Panorama Remedies Limited	AAEC P0204 E	The entity, or any member of a group of which it is a part, provides key management personnel service to the reporting entity or parent of the reporting entity	Purchase of goods	10,00,000/-	86907/-	-	86907/-	-	-	-		-	-	-	
						Amount Paid on behalf of Parenteral Drugs (India) Limited		508200/-	-	508200/-	-	-	-		-	-	-	
6	Parenteral Drugs (India) Limited	AAAC P2820L	IHL Medicare Private Limited	AAEC I8295 A	The entity, or any member of a group of which it is a part, provides key management personnel service to the reporting entity or parent of the reporting entity	Purchase of goods	1,00,00,000/-	53,08,811/-	-	53,08,811/-	-	-	-		-	-	-	
						Amount Paid on behalf of Parenteral Drugs (India) Limited		39,14,261/-	-	39,14,261/-	-	-	-		-	-	-	
7	Parenteral Drugs (India) Limited	AAAC P2820L	Mr. Vinod Kumar Gupta	AAAP G9923 G	Managing Director	Loan Taken	-	Nil	2,69,762/-	2,69,762/-	-	-	-	Loan Taken	-		Unsecured Loan	
8	Parenteral Drugs (India) Limited	AAAC P2820L	Mr. Govind Das Garg	AETP G5359 P	Whole-Time Director	Loan Taken	-	Nil	56,640/-	56,640/-	-	-	-	Loan Taken	-		Unsecured Loan	
9	Parenteral Drugs (India) Limited	AAAC P2820L	Mr. Lalit Mittal	AAHP M168 3Q	Person or a close members has control, significant influence on the reporting entity or is member of KMP in reporting entity.	Remuneration including Perks	-	7,000/-	12,00,000/-	12,07,000/-	-	-	-	-	-		-	
10	Parenteral Drugs (India) Limited	AAAC P2820L	Mr. Dharam Pal Khanna	ACNP K4907 H	Independent Director	Sitting Fees	-	16000/-	-	-	-	-	-	-	-		-	
11	Parenteral Drugs (India) Limited	AAAC P2820L	Mr. Dilip Kumar Sinha	AGPP S3126 C	Independent Director	Sitting Fees	-	12000/-	-	-	-	--	-	-	-		-	

12	Parenteral Drugs (India) Limited	AAAC P2820L	Mrs. Deepali Garhewal	AKAP G1382 K	Independent Director	Sitting Fees	-	6000/-	-	-	-	-	-	-	-	-	-
13	Parenteral Drugs (India) Limited	AAAC P2820L	Mr. Manish Verma	AFRP V0629 Q	Independent Director	Sitting Fees	-	10000/-	-	-	-	-	-	-	-	-	-
14	Parenteral Drugs (India) Limited	AAAC P2820L	Mrs. Chhaya Gupta	AGUP G5947 N	Independent Director	Sitting Fees	-	4000/-	-	-	-	-	-	-	-	-	-
Total (of Note 6b)								176046549/-									

Notes:

- The details in this format are required to be provided for all transactions undertaken during the reporting period. However, opening and closing balances, including commitments, to be disclosed for existing related party transactions even if there is no new related party transaction during the reporting period.
- Where a transaction is undertaken between members of the consolidated entity (between the listed entity and its subsidiary or between subsidiaries), it may be reported once.
- Listed banks shall not be required to provide the disclosures with respect to related party transactions involving loans, inter-corporate deposits, advances or investments made or given by the listed banks.
- For companies with financial year ending March 31, this information has to be provided for six months ended September 30 and six months ended March 31. Companies with financial years ending in other months, the six months period shall apply accordingly.
- Each type of related party transaction (for e.g. sale of goods/services, purchase of goods/services or whether it involves a loan, inter-corporate deposit, advance or investment) with a single party shall be disclosed separately and there should be no clubbing or netting of transactions of same type. However, transactions with the same counterparty of the same type may be aggregated for the reporting period. For instance, sale transactions with the same party may be aggregated for the reporting period and purchase transactions may also be disclosed in a similar manner. There should be no netting off for sale and purchase transactions. Similarly, loans advanced to and received from the same counterparty should be disclosed separately, without any netting off.
- In case of a multi-year related party transaction:
 - The aggregate value of such related party transaction as approved by the audit committee shall be disclosed in the column “Value of the related party transaction as approved by the audit committee”.
 - The value of the related party transaction undertaken in the reporting period shall be reported in the column “Value of related party transaction during the reporting period”.
- "Cost" refers to the cost of borrowed funds for the listed entity.
- PAN will not be displayed on the website of the Stock Exchange(s).

9. Transactions such as acceptance of fixed deposits by banks/NBFCs, undertaken with related parties, at the terms uniformly applicable /offered to all shareholders/ public shall also be reported.

*